ALK+ and ALK- anaplastic large cell lymphomas (ALCL) are rare lymphomas, a type of peripheral T-cell lymphoma that develops in white blood cells called T-cells (a type of white blood cells that normally help fight infection, also called T-lymphocytes).
One of the objectives of the REALYSA study is to get a better understanding of the profile of adult patients diagnosed with different lymphomas in France, their care pathway, the treatments they receive and their response to treatments. Real world data, collected during routine clinical practice, as in the REALYSA study, are not widely available in France and will be useful to all the stakeholders involved in the care of patients with lymphoma, ultimately for the benefit of patients.
Brentuximab Vedotin (Adcetris®) is a monoclonal anti-CD30 antibody combined with a cytotoxic molecule commercialised by TAKEDA. This medicine was granted a marketing authorisation in several indications, including patients with anaplastic large cell lymphoma.
TAKEDA wish to improve their understanding of the profile, care and needs of patients diagnosed with ALCL. TAKEDA was interested to get a descriptive report presenting the profile of the patients included in REALYSA who received Adcetris® in this indication, as well as treatments received and response to treatments.
With this project, TAKEDA will also obtain data on the use of Adcetris® in current practice for patients with ALCL. TAKEDA will thus be able to provide data on the use of this drug to the High Authority of Health, administrative authority in charge of medicine use in France.
For this project, TAKEDA will receive a descriptive report where the results will be aggregated and anonymised. The company will not receive any individual data.
To all patients participating in REALYSA, and more particularly for patients with anaplastic large cell lymphoma: if you wish to object to the use of your data for this analysis, you can contact your doctor at the care centre who invited you to take part in REALYSA or make a request at dpo@lysarc.org, as described in the Patient Information Leaflet you received at the beginning of your participation in the study. You can find in this document all the information on your rights regarding your personal data. The first data extraction, for the 2022 report, is scheduled for March 4th 2022.